Christopher J. Kirk

Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Susan D. Demo, Christopher J. Kirk, Monette Aujay et al. · Cancer Research · 2007 · 675 citations · Full text

Medicine, Oncology, Pharmacology +13

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

E.M. Huber, Michael Basler, Ricarda Schwab et al. · Cell · 2012 · 494 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Hormonal Stimulation of Phosphatidylinositol Breakdown, with Particular Reference to the Hepatic Effects of Vasopressin

Robert H. Michell, Christopher J. Kirk, M. M. BILLAH · Biochemical Society Transactions · 1979 · 436 citations

Life Sciences, Biochemistry, Physiology +8

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

Shirin Arastu‐Kapur, Janet L. Anderl, Marianne Kraus et al. · Clinical Cancer Research · 2011 · 409 citations

Medicine, Pharmacology, Pharmacotherapy +15

Stepwise enzymatic dephosphorylation of inositol 1,4,5-trisphosphate to inositol in liver

D J Storey, Stephen B. Shears, Christopher J. Kirk et al. · Nature · 1984 · 323 citations

Life Sciences, Biochemistry, Molecular Biology +11